Clinical management of medulloblastoma in adults

References

• Giordana MT, Schiffer P, Lanotte M et al Epidemiology of adult medulloblastoma. Int.j Cancer 80,689–692 (1999).
   PubMed Web of Science ®Google Scholar
• Roberts RO, Lynch CF, Jones MP, Hart MN. Medulloblastoma: a population-based study of 532 cases. J. Neuropathol Exp. Neural. 50,134-144 (1991).
   Google Scholar
• Brandes AA, Ermani M, Amista P et al. The treatment of adults with medulloblastoma: a prospective study. Int. J. Racliat. Once]. Bid Phys. 57,755–761 (2003).
   PubMed Web of Science ®Google Scholar
• •Recent prospective clinical trial (Phase In of adult medulloblastoma offering treatment stratified for risk group based on classic parameters.
   Google Scholar
• Boissel N, Auclerc MF, Lhéritier V et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. 1 Clin. Once]. 21,774-780 (2003).
   Google Scholar
• Schiffer CA. Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both? J. Clin. Once]. 21,760–761 (2003).
   PubMed Web of Science ®Google Scholar
• Albright AL, Sposto R, Holmes E et al Correlation of neurosurgical subspecialization with outcomes in children with malignant brain tumors. Neurosurgery 47,879–885 (2000).
   PubMed Web of Science ®Google Scholar
• Zeltzer PM, Boyett JM, Finlay JL et al Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized Phase III study. J. Clin. Oncol 17,832–845 (1999).
   Google Scholar
• •Clearly delineated prognostic groups in childhood medulloblastoma and provided a basis for the design of prospective randomized clinical trials for average- and poor-risk patients.
   Google Scholar
• Kortmann RD, Kahl J, Timmermann B et al Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91. Int. j Racliat. Once]. Bid Phys. 46,269-279 (2000).
   Google Scholar
• Taylor RE, Bailey CC, Robinson K et al Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 study.j Clin. Oncol 21,1581–1591 (2003).
   Google Scholar
• Thomas PRM, Deutsch M, Kepner JL et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J. Clin. Once]. 18,3004-3011 (2000). itPacker RJ, Goldwein J, Nicholson HS et al Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children's Cancer Group study. J Clin. Oncoll7, 2127–2136 (1999).
   Google Scholar
• ••Landmark study demonstrating thatcraniospinal radiation can be reduced safely from 36 to 24.3 Gy with the provision of adjuvant chemotherapy in children with average-risk medulloblastoma.
   Google Scholar
• Packer R, Gajjar A, Vezina G et al. Preliminary report of A9961: a Phase III randomized study of craniospinal radiotherapy (CSRT) followed by one of two adjuvant chemotherapy regimens (CCNU, CPDD, VCR or CPM, CPDD, VCR) in children with newly diagnosed average-risk medulloblastoma (MB). Proc. Int. Symp. Pecliatr. Neurooncol (2004) (Abstract Then 61).
   Google Scholar
• Ellison DW, Clifford SC, Gajjar A, Gilbertson RJ. What's new in neuro-oncology? Recent advances in medulloblastoma. Eur. j Pecliatr. Neural.7, 53–66 (2003).
   PubMed Web of Science ®Google Scholar
• •Comprehensive review of current treatment strategies and translational research in medulloblastoma.
   Google Scholar
• Fisher PG, Burger PC, Eberhart CG. Biologic risk stratification of medulloblastoma: the real time is now. Clin. Oncol 22,971–974 (2004).
   Google Scholar
• ••Outstanding review of the application ofclinical features, microarray data and molecular markers to determine prognostic risk factors in medulloblastoma.
   Google Scholar
• Gilbertson RJ. Medulloblastoma: signalling a change in treatment. Lancet Once]. 5, 209–218 (2004).
   PubMed Web of Science ®Google Scholar
• ••Excellent review of clinical, pathologic andbiomolecular studies, as well as an overview of the shift towards the utilization of targeted therapies in selected patients.
   Google Scholar
• Wolden SL, Dunkel IJ, Souweidane MM et al Patterns of failure using a conformal radiation therapy tumor bed boost for medulloblastoma. j Clin. Once]. 21, 3079–3083 (2003).
   PubMed Web of Science ®Google Scholar
• Carrie C, Lasset C, Alapetite C et al. Multivariate analysis of prognostic factors in adult patients with medulloblastoma. Retrospective study of 156 patients. Cancer 74, 2352–2360 (1994).
   Google Scholar
• •Largest retrospective case series in adults, although not all cases were exclusively imaged with magnetic resonance imaging.
   Google Scholar
• Frost PJ, Laperriere NJ, Wong CS et al. Medulloblastoma in adults. int. j Radiat. Oncol Biol. Phys. 32, 951–957 (1995).
   PubMed Web of Science ®Google Scholar
• Prados MD, Warnick RE, Wara WM et al. Medulloblastoma in adults. int. j Radiat. Oncol Biol. Phys. 32, 1145–1152 (1995).
   PubMed Web of Science ®Google Scholar
• •First retrospective adult study to recommend that the principles of management of pediatric medulloblastoma should be applied to adults.
   Google Scholar
• Chan AW, Tarbell NJ, Black PM et al. Adult medulloblastoma: prognostic factors and patterns of relapse. Neumsurgay47, 623–632 (2000).
   PubMed Web of Science ®Google Scholar
• Chang CH, Housepian EM, Hebert C Jr. An operative staging system and a megavoltage radiotherapeutic technique for cerebellar medulloblastomas. Radiology 93, 1351–1359 (1969).
   Google Scholar
• •Classic paper in neuro-oncology.
   Google Scholar
• Greenberg HS, Chamberlain MC, Glantz MJ, Wang S. Adult medulloblastoma: multiagent chemotherapy. Neurooncology3, 29–34 (2001).
   PubMed Web of Science ®Google Scholar
• Kunschner LJ, Kuttesch J, Hess K, Yung WKA. Survival and recurrence factors in adult medulloblastoma: the MD Anderson Cancer Center experience from 1978 to 1998. Neurooncology3, 167–173 (2001).
   PubMed Web of Science ®Google Scholar
• Abacioglu U, Uzel O, Sengoz M etal. Medulloblastoma in adults: treatment results and prognostic factors. int../ Radiat. Oncol Biol. Phys. 54, 855–860 (2002).
   Google Scholar
• Malheiros SMF, Franco CMR, Stavale JN et al. Medulloblastoma in adults. J. Neurooncol 60, 247–253 (2002).
   PubMed Web of Science ®Google Scholar
• Malheiros SMF, Carrete H Jr, Stavale JN et al. MRI of medulloblastoma in adults. Neuroradiology45, 463–467 (2003).
   PubMed Web of Science ®Google Scholar
• Giordana MT, Cavalla P, Chio A et al Prognostic factors in adult medulloblastoma. A clinico-pathologic study. Tumori 81, 338–346 (1995).
   Google Scholar
• Sarkar C, Pramanik P, Karak AK et al. Are childhood and adult medulloblastomas different? A comparative study of clinicopathological features, proliferation index and apoptotic index. J. Neurooncol 59, 49–61 (2002).
   PubMed Web of Science ®Google Scholar
• Giordana MT, Duo D, Gasverde S et al. MDM2 overexpression is associated with short survival in adults with medulloblastoma. Neurooncology4, 115–122 (2002).
   PubMed Web of Science ®Google Scholar
• Zia MI, Forsyth P, Chaudry A et al Possible benefits of high-dose chemotherapy and autologous stem cell transplantation for adults with recurrent medulloblastoma. Bone Man ow 7iamplant. 30, 565–569 (2002).
   Google Scholar
• Millot F, Delval O, Giraud C et al High dose chemotherapy with hematopoietic stem cell transplantation in adults with bone marrow relapse of medulloblastoma: report of two cases. Bone Matrow Transplant. 24, 1347–1349 (1999).
   PubMed Web of Science ®Google Scholar
• Carrie C, Hoffstetter S, Gomez F et al Impact of targeting deviations on outcome in medulloblastoma: study of the French Society of Pediatric Oncology (SFOP). Int. Radiat. Oncol Biol. fiyc. 45, 435–439 (1999).
   PubMed Web of Science ®Google Scholar
• Gajjar A, Fouladi M, Walter AW et al Comparison of lumbar and shunt cerebrospinal fluid specimens for cytologic detection of leptomeningeal disease in pediatric patients with brain tumors. J. Clin. Oncol 17,1825–1828 (1999).
   PubMed Web of Science ®Google Scholar
• •Confirms the superiority of lumbar cerebrospinal fluid in the clinical staging of patients with medulloblastoma.
   Google Scholar
• Fouladi M, Gajjar A, Boyett JM et al Comparison of CSF cytology and spinal magnetic resonance imaging in the detection of leptomeningeal disease in pediatric medulloblastoma or primitive neuroectodermal tumor. J. Clin. Oncol 17, 3234–3237 (1999).
   PubMed Web of Science ®Google Scholar
• Eberhart CG, Cohen KJ, Tihan T et al Medulloblastomas with systemic metastases: evaluation of tumor histopathology and clinical behavior in 23 patients. .1. Pediatr Hematol Oncol 25, 198–203 (2003).
   Google Scholar
• Brown HG, Kepner JL, Perlman EJ et al Large cell/anaplastic medulloblastomas: a Pediatric Oncology Group Study. Neuropathol Exp. Nemo'. 59, 857–65 (2000).
   PubMed Web of Science ®Google Scholar
• Eberhart CG, Kepner JL, Goldthwaite PT et al Histopathologic grading of medulloblastoma: a Pediatric Oncology Group Study. Cancer94, 552–560 (2002).
   PubMed Web of Science ®Google Scholar
• •Important contribution documenting large cell/anaplastic medulloblastoma as an independent prognostic factor in pediatric medulloblastoma.
   Google Scholar
• Freeman CR, Taylor RE, Kortman RD, Carrie C. Radiotherapy for medulloblastoma in children: a perspective on current international clinical research efforts. Med. Pediatr Oncol 39, 99–108 (2002).
   PubMedGoogle Scholar
• Merchant TE, Kun LE, Krasin MJ et al A multi-institution prospective trial of reduced dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma. kit. J. Radiat. Oncol Biol. Phys. 57 (Suppl.), S194—S195 (2003).
   Google Scholar
• Carrie C, Muracciole X, Gomez F et al Conformal radiotherapy, reduced boost volume, hyperfractionated radiotherapy and on-line quality control in standard risk medulloblastoma without chemotherapy. Results of the French M-SFOP 98 protocol. Int. .1. Radiat. Oncol Biol. Phys. 57(Suppl.), S195 (2003).
   Google Scholar
• Tabori U, Hukin J, Crooks B et al. Medulloblastoma in the second decade of life: a specific group with respect to toxicity and management. A Canadian Paediatric Brain Tumor Consortium Study. Proc. hit. Symp. Pediatr Neumoncol (2004) (Abstract Then 77).
   Google Scholar
• Fernandez-Teijeiro A, Betensky RA, Sturla LM et al Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. Clin. Oncol 22, 1–5 (2004).
   Web of Science ®Google Scholar
• •One of the first applications of gene expression profiling combined with clinical risk factors used to determine prognosis in pediatric medulloblastoma.
   Google Scholar
• Gajjar A, Heman R, Kocak M etal. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. j Clin. Oncol 22, 984–993 (2004).
   Google Scholar
• •Another recent paper combining clinicopathologic and molecular studies to assign prognosis in patients with medulloblastoma.
   Google Scholar